Homocysteine

Homocysteine

SCHEMBL601148

N[C@H](CCS)C(=O)O

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Homocysteine SCHEMBL28927454 1.00 PTGS1 (0.62)
L-Homocysteine SCHEMBL936366 1.00 PTGS1 (0.62)
Homocysteine SCHEMBL35836 1.00
L-Homocysteine SCHEMBL35837 1.00
Homocysteine SCHEMBL936365 1.00 PTGS1 (0.62)
L-Homocysteine SCHEMBL23721811 0.97 PTGS1 (0.59)
Homocysteine SCHEMBL3326967 0.97
Homocysteine SCHEMBL2513065 0.97 PTGS1 (0.59)
L-Homocysteine SCHEMBL2513063 0.97 PTGS1 (0.59)
Homocysteine SCHEMBL1534779 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 800 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260085092-A1 MELANOCORTIN RECEPTOR LIGANDS IPSEN PHARMA SAS (FR) 2026-03-26 US claimed
EP-4711004-A2 METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS Rhythm Pharmaceuticals, Inc. (US) 2026-03-18 EP claimed
US-20260001915-A1 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST RHYTHM PHARMACEUTICALS INC (US) 2026-01-01 US claimed
US-20250195606-A1 METHOD OF TREATING MELANOCORTIN-4 RECEPTOR PATHWAY-ASSOCIATED DISORDERS CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) 2025-06-19 US claimed
CN-120152725-A Methods of treating obesity using MC4R agonists 节奏制药公司 2025-06-13 CN claimed
US-20250163103-A1 THERAPEUTIC AGENTS FOR REDUCING PARATHYROID HORMONE LEVELS KAI PHARMACEUTICALS, INC. 2025-05-22 US claimed
EP-4554607-A2 METHODS FOR TREATING OBESITY WITH AN MC4R AGONIST Rhythm Pharmaceuticals, Inc. (US) 2025-05-21 EP claimed
US-20250129125-A1 MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2025-04-24 US claimed
WO-2025072586-A1 CHAIN TRANSFER AGENTS AND METHODS OF PREPARING THE SAME ARKEMA INC. (US) 2025-04-03 WO claimed
US-12263202-B2 Method of treating melanocortin-4 receptor pathway-associated disorders RHYTHM PHARMACEUTICALS, INC. (US) 2025-04-01 US claimed
US-20090176715-A1 Pharmaceutical Compositions and Methods Utilizing a D-Amino Acid AMINO ACIDS SOLUTIONS INC. (US) 2009-07-09 US claimed
US-7335292-B2 Metal electrode coated with an organosulfur compounds, especially 2-mercaptoethanol, 2-mercaptoethylamine, 3-mercaptopropionic acid, thiophene, cysteine, homocysteine, 3-carboxythiophene, or cystine; surfactant overcoating LIFESCAN, INC. (US) 2008-02-26 US claimed
US-7163920-B2 Peptide with osteogenic activity ETHICON, INC. (US) 2007-01-16 US claimed
US-20060040324-A1 Methods for making metallopeptides and metallopeptide libraries PALATIN TECHNOLOGIES, INC. (US) 2006-02-23 US claimed
US-20050187162-A1 Novel peptide with osteogenic activity ETHICON, INC. 2005-08-25 US claimed
WO-2005032461-A2 NOVEL PEPTIDE WITH OSTEOGENIC ACTIVITY ETHICON, INC. (US) 2005-04-14 WO claimed
US-4605625-A RACEMIZATION WITH PSEUDOMONAS NIPPON ZEON CO., LTD. (JP) 1986-08-12 US claimed
EP-0010668-B1 3-DEAZAADENOSINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT THE WELLCOME FOUNDATION LIMITED (GB) 1986-01-22 EP claimed
US-4309419-A 3-DEAZA-ADENOSINE BURROUGHS WELLCOME CO. (US) 1982-01-05 US claimed
EP-0010668-A1 3-Deazaadenosine and pharmaceutical compositions containing it THE WELLCOME FOUNDATION LIMITED (GB) 1980-05-14 EP claimed